The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Research Report 2024

Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1739790

No of Pages : 90

Synopsis
After vaccination, the body can produce a humoral immune response. It is used to prevent infectious diseases caused by group A and group C meningococci, such as cerebrospinal meningitis and pneumonia.

Global Group A and Group C Meningococcal Polysaccharide Vaccine market is projected to reach US$ 425.5 million in 2029, increasing from US$ 285 million in 2022, with the CAGR of 5.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Group A and Group C Meningococcal Polysaccharide Vaccine market research.
Meningococcal disease, caused by Neisseria meningitidis, can cause serious illness and even death. The global burden of meningococcal disease, especially serogroups A and C, drives the need for effective vaccines to prevent these infections.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Group A and Group C Meningococcal Polysaccharide Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Walvax
  • Lanzhou Institute of Biological Products
  • AIM Bio
  • Sanofi Pasteur
  • GSK
  • Hualan Bio
  • ZFSW
  • Changsheng
  • Kanghua Bio

Segment by Type

  • Class 1 Vaccine
  • Class II Vaccine

Segment by Application

  • Hospital
  • Clinic

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Group A and Group C Meningococcal Polysaccharide Vaccine report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Group A and Group C Meningococcal Polysaccharide Vaccine Market Overview
1.1 Product Overview and Scope of Group A and Group C Meningococcal Polysaccharide Vaccine
1.2 Group A and Group C Meningococcal Polysaccharide Vaccine Segment by Type
1.2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 Class 1 Vaccine
1.2.3 Class II Vaccine
1.3 Group A and Group C Meningococcal Polysaccharide Vaccine Segment by Application
1.3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size Estimates and Forecasts
1.4.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue 2018-2029
1.4.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales 2018-2029
1.4.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Group A and Group C Meningococcal Polysaccharide Vaccine Market Competition by Manufacturers
2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Group A and Group C Meningococcal Polysaccharide Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Group A and Group C Meningococcal Polysaccharide Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Group A and Group C Meningococcal Polysaccharide Vaccine, Product Type & Application
2.7 Group A and Group C Meningococcal Polysaccharide Vaccine Market Competitive Situation and Trends
2.7.1 Group A and Group C Meningococcal Polysaccharide Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Group A and Group C Meningococcal Polysaccharide Vaccine Players Market Share by Revenue
2.7.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Group A and Group C Meningococcal Polysaccharide Vaccine Retrospective Market Scenario by Region
3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region: 2018-2029
3.2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region: 2018-2023
3.2.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region: 2024-2029
3.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region: 2018-2029
3.3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region: 2018-2023
3.3.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region: 2024-2029
3.4 North America Group A and Group C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
3.4.1 North America Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2018-2029)
3.4.3 North America Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
3.5.1 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2018-2029)
3.5.3 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Group A and Group C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
3.7.1 Latin America Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2018-2029)
4.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2018-2023)
4.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2024-2029)
4.1.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Type (2018-2029)
4.2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Type (2018-2023)
4.2.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Type (2024-2029)
4.2.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2018-2029)
5.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2018-2023)
5.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2024-2029)
5.1.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Application (2018-2029)
5.2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Application (2018-2023)
5.2.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Application (2024-2029)
5.2.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Walvax
6.1.1 Walvax Corporation Information
6.1.2 Walvax Description and Business Overview
6.1.3 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio
6.1.5 Walvax Recent Developments/Updates
6.2 Lanzhou Institute of Biological Products
6.2.1 Lanzhou Institute of Biological Products Corporation Information
6.2.2 Lanzhou Institute of Biological Products Description and Business Overview
6.2.3 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio
6.2.5 Lanzhou Institute of Biological Products Recent Developments/Updates
6.3 AIM Bio
6.3.1 AIM Bio Corporation Information
6.3.2 AIM Bio Description and Business Overview
6.3.3 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio
6.3.5 AIM Bio Recent Developments/Updates
6.4 Sanofi Pasteur
6.4.1 Sanofi Pasteur Corporation Information
6.4.2 Sanofi Pasteur Description and Business Overview
6.4.3 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio
6.4.5 Sanofi Pasteur Recent Developments/Updates
6.5 GSK
6.5.1 GSK Corporation Information
6.5.2 GSK Description and Business Overview
6.5.3 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio
6.5.5 GSK Recent Developments/Updates
6.6 Hualan Bio
6.6.1 Hualan Bio Corporation Information
6.6.2 Hualan Bio Description and Business Overview
6.6.3 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio
6.6.5 Hualan Bio Recent Developments/Updates
6.7 ZFSW
6.6.1 ZFSW Corporation Information
6.6.2 ZFSW Description and Business Overview
6.6.3 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio
6.7.5 ZFSW Recent Developments/Updates
6.8 Changsheng
6.8.1 Changsheng Corporation Information
6.8.2 Changsheng Description and Business Overview
6.8.3 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio
6.8.5 Changsheng Recent Developments/Updates
6.9 Kanghua Bio
6.9.1 Kanghua Bio Corporation Information
6.9.2 Kanghua Bio Description and Business Overview
6.9.3 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio
6.9.5 Kanghua Bio Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Group A and Group C Meningococcal Polysaccharide Vaccine Industry Chain Analysis
7.2 Group A and Group C Meningococcal Polysaccharide Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Group A and Group C Meningococcal Polysaccharide Vaccine Production Mode & Process
7.4 Group A and Group C Meningococcal Polysaccharide Vaccine Sales and Marketing
7.4.1 Group A and Group C Meningococcal Polysaccharide Vaccine Sales Channels
7.4.2 Group A and Group C Meningococcal Polysaccharide Vaccine Distributors
7.5 Group A and Group C Meningococcal Polysaccharide Vaccine Customers
8 Group A and Group C Meningococcal Polysaccharide Vaccine Market Dynamics
8.1 Group A and Group C Meningococcal Polysaccharide Vaccine Industry Trends
8.2 Group A and Group C Meningococcal Polysaccharide Vaccine Market Drivers
8.3 Group A and Group C Meningococcal Polysaccharide Vaccine Market Challenges
8.4 Group A and Group C Meningococcal Polysaccharide Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’